BiomX Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
BiomX has undergone a complete corporate transformation, abandoning its phage-therapy biopharmaceutical business following the insolvency of its Israeli operating subsidiary and pivoting entirely to defense, security, and critical infrastructure technology through newly acquired Israeli subsidiaries. The company disclosed that disclosure controls are not effective, faces NYSE American delisting risk due to a stockholders' deficit, and is executing highly dilutive equity sales at sub-$0.50 share prices to fund operations. Legacy legal/bankruptcy proceedings (BiomX Ltd. insolvency, APT Chapter 7 filing, Emmes litigation) compound uncertainty around this unproven new business strategy.
Red Flags Detected (9)
Disclosure controls and procedures explicitly deemed NOT effective as of June 30, 2026
Stockholders' deficit of $(1.3) million triggering NYSE American non-compliance under three separate listing standards
Common Stock trading below $0.50/share, with further declines reported after quarter-end
6 more red flags detected
Key Takeaways
BiomX has effectively exited the phage-therapy biopharmaceutical business and reinvented itself as a defense/security technology holding company within the current quarter
The company faces simultaneous going-concern-type pressures: insolvency of former subsidiary, bankruptcy of another subsidiary, ineffective controls, and stock exchange delisting risk
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.